MSHLRamucirumab Concentrate For Solution For Infusion 100 mg/10 mL, 500 mg/50 mL
1) Treatment of advanced unresectable hepatocellular carcinoma in patients with disease progression after 1 or more prior lines of systemic therapy, and who have serum alpha-fetoprotein (AFP) of ≥400 ng/ml, and have adequate liver function as assessed by the Child-Pugh scoring system.
2) Ramucirumab as monotherapy for patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.
3) Ramucirumab in combination with paclitaxel for patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.
4) Ramucirumab in combination with FOLFIRI for treating metastatic colorectal cancer that has progressed on first-line systemic therapy.